|
Pt. no.
|
Demographics & HHT features
|
Topical propranolol treatment -- duration and outcome measures
|
|---|
|
Age/ gender (M/F)
|
HHT mutation
|
Other HHT features
|
Treatment duration (wks)
|
ESS before/ after 12 wks treatment
|
Hb (gr%) before/after 12 wks treatment
|
PC before treatment/after 12 wks/after 24 wks
|
|---|
|
1
|
72/M
|
Endoglin
|
PAVMs, GI bleed
|
48
|
7.3/1.5
|
7.4/10.9
|
10/3/0
|
|
2
|
55/F
|
Endoglin
|
HAVMs, GI bleed
|
12
|
4.4/1.9
|
12/12
|
–
|
|
3
|
68/F
|
ACVRL-1
|
PAVMs, HAVMs
|
38
|
10/5.9
|
5.4/9.9
|
9/6/0
|
|
4
|
41/M
|
ACVRL-1
|
PAVMs
|
34
|
4.4/2.5
|
12.5/14
|
–
|
|
5
|
37/F
|
ACVRL-1
|
None
|
26
|
6.2/4.2
|
6.1/10
|
–
|
|
6
|
76/F
|
Not done
|
HAVMs
|
26
|
6.4/4.9
|
7.1/9.1
|
8/6/2
|
|
p
| | |
0.028a
|
0.043a
|
0.109a (12 weeks) 0.109a (24 weeks)
|
-
aWilcoxon signed-rank test
- Abbreviations: ESS epistaxis severity score, GI gastrointestinal, HAVMs hepatic arteriovenous malformations, Hb hemoglobin, PAVMs pulmonary arteriovenous malformations, PC packed red cells
